Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Launch of CSR programme

13 Mar 2012 07:00

RNS Number : 2001Z
Cello Group plc
13 March 2012
 



13 March 2012

 

Cello Group plc

 

Launch of CSR programme

 

Cello Group plc (AIM:CLL, 'Cello', or 'the Group'), the insight and strategic marketing group, has today launched its new Corporate Social Responsibility programme 'Talking Taboos'. 

 

Talking Taboos is a campaigning brand that aims to directly tackle health and social issues using Cello's experience and resources in the healthcare space. It will focus on areas where embarrassment, fear or ignorance prevents sufferers from seeking help.

 

For 2012, Talking Taboos will be addressing teen mental health, specifically self-harm, through an extensive research project with the teen charity YoungMinds. The research will examine the context in which teenagers find themselves when actively self-harming, and will attempt to inform parents, teachers, peers and health professionals how best to identify and support at-risk and self-harming teens.

Each Cello Group company will utilise its expertise in methodology or market sector to contribute to a 'whole community' view that will help carers and sufferers by providing context, exploding myths and challenging prevailing attitudes to self-harm. The programme is being led by Vincent Nolan, Group Chairman of Cello Research and Consulting, and the Group is planning to expand this initiative in the future to assist organisations which address a range of health related issues.

Mark Scott, Cello Group CEO, said:

 

"Talking Taboos is a great opportunity for us to support a worthwhile cause in the best way we know how - through our market leading research and our wealth of experience in working with health issues.

 

"It is also an ideal way for our companies to demonstrate their abilities and talents and work across the group to deliver a comprehensive project that should help change the way that self-harm is perceived and handled."

 

 

Enquiries:

 

Cello Group plc (www.cellogroup.com)

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

Vincent Nolan, Group Chairman - Cello Research and Consulting

020 7655 9900

Cenkos

Bobbie Hilliam

020 7397 8900

College Hill

Kay Larsen/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.com)

 

Cello is an insight and strategic marketing group.

 

The Group's strategy is to create value for shareholders by building an international research and consulting business able to advise blue chip clients globally, along with a marketing business capable of delivering world class solutions.

 

Cello has annualised revenues in excess of £130m, annualised gross profit in excess of £65m and employs over 700 professional staff.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGUUWWUPPGMP
Date   Source Headline
20th Jul 202012:21 pmRNSForm 8.3 - Cello Health Plc
17th Jul 20209:14 amRNSForm 8.3 - Cello Health PLC
16th Jul 20205:00 pmRNSForm 8.3 - Cello Health plc
16th Jul 20208:48 amRNSForm 8.3 - Cello Health PLC
16th Jul 20207:00 amRNSForm 8.3 - Cello Health Plc
15th Jul 20203:00 pmRNSUpdate re: antitrust clearances
15th Jul 20201:44 pmRNSForm 8.3 - Cello Health Plc
15th Jul 20201:21 pmRNSHolding(s) in Company
15th Jul 20208:55 amRNSForm 8.3 - Cello Health PLC
14th Jul 20201:33 pmRNSForm 8.3 - Cello Health plc
14th Jul 20208:51 amRNSForm 8.3 - Cello Health PLC
14th Jul 20208:04 amRNSHolding(s) in Company
14th Jul 20207:01 amRNSHolding(s) in Company
13th Jul 20203:15 pmBUSForm 8.3 - Cello Health plc
13th Jul 202010:51 amBUSForm 8.3 - CELLO HEALTH PLC
13th Jul 20208:18 amRNSForm 8.3 - Cello Health PLC
13th Jul 20207:00 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSPublication of Scheme Document
10th Jul 20203:20 pmRNSForm 8.3 - Cello Health Plc
10th Jul 20203:17 pmRNSForm 8.3 - Cello Health PLC
10th Jul 20203:10 pmPRNForm 8.3 - Cello Health Plc
10th Jul 20201:34 pmBUSForm 8.3 - CELLO HEALTH PLC
10th Jul 202010:11 amRNSHolding(s) in Company
10th Jul 20209:41 amRNSForm 8.3 - Cello Health Plc
10th Jul 20208:51 amRNSForm 8.3 - Cello Health PLC
9th Jul 20206:20 pmRNSUpdate on letters of intent
9th Jul 20205:38 pmRNSHolding(s) in Company
9th Jul 20203:20 pmRNSForm 8.3 - Cello Health
9th Jul 20203:17 pmRNSForm 8.3 - CELLO HEALTH PLC
9th Jul 20203:08 pmRNSForm 8.3 - Cello Health PLC
9th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
9th Jul 202012:33 pmRNSHolding(s) in Company
9th Jul 202011:31 amRNSForm 8.3 - Cello Health Plc
9th Jul 20209:20 amRNSForm 8.3 - Cello Health plc
9th Jul 20209:10 amRNSForm 8.3 - Cello Health PLC
9th Jul 20207:00 amRNSUpdate on irrevocable undertakings
8th Jul 20203:56 pmPRNForm 8.3 - Cello Health Plc
8th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
8th Jul 20202:00 pmRNSForm 8.3 - Cello Health Plc
8th Jul 202012:45 pmRNSForm 8.3 - Cello Health plc
8th Jul 202010:35 amRNSForm 8.3 - Cello Health PLC
8th Jul 20209:55 amRNSForm 8.3 - Cello Health plc
8th Jul 20208:54 amPRNForm 8.3 - Cello Health plc
8th Jul 20207:00 amRNSUpdate on irrevocable undertakings
8th Jul 20207:00 amRNSForm 8.3 - Cello Health PLC
7th Jul 20203:20 pmRNSForm 8.3 - Cello Health
7th Jul 20203:19 pmRNSForm 8.3 - CELLO HEALTH PLC
7th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
7th Jul 202010:08 amRNSCELLO HEALTH PLC
7th Jul 20209:16 amPRNForm 8.3 - Cello Health Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.